Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23983763 | 0.96 | NPC1 (0.31) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23984102 | 0.93 | NPC1 (0.30) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23983594 | 0.92 | NPC1 (0.31) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23129128 | 0.89 | CYP1A2 (0.36) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23983963 | 0.89 | — | — | |
| SCHEMBL23983604 | 0.88 | TDP1 (0.32) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23129601 | 0.88 | NPC1 (0.30) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23129408 | 0.87 | NPC1 (0.33) | NPC1CYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL23984018 | 0.87 | NQO1 (0.32) | RAB9A | |
| SCHEMBL26973747 | 0.86 | TDP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210340159-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG CHEM, LTD. (KR) | 2021-11-04 | — | — | US | disclosed |
| EP-3795569-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME | LG CHEM, LTD. (KR) | 2021-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340159-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | NR4A1, CYP1A1, ARNT | NPC1 2374/4885CYP1A2 36/4885CYP2C9 76/4885 |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | NR4A1, CYP1A1, ARNT | NPC1 2374/4885CYP1A2 36/4885CYP2C9 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.